Key Drivers
- Margin Pressure
- Cash Flow Drop
- Leverage Spike
AIAI Summary
ALKS has evolved from a steady cash-generative CNS name into a catalyst-driven sleep franchise story, but the investment case now hinges on whether LUMRYZ/Alixorexton growth can restore operating leverage and free cash flow before the new net-debt balance sheet and volatile expense profile cap upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Pressure
- •Cash Flow Drop
- •Leverage Spike
ALKS had a strong 2025 base, but the latest quarter showed a sharp deterioration in profits, cash flow, and leverage, making the near-term outlook more cautious. ക
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout hold
- •Near resistance
Over the last month, ALKS has built a constructive uptrend with higher highs/lows above $35.00, but after pulling back from $38.91 it is now at a short-term inflection point between $35.00-$35.50 support and $38.9-$39.0 resistance.
Recent pullback from the $38.91 peak signals cooling momentum
Sentiment & News
Key News Insights:
- •Earnings beat
- •LUMRYZ success
- •Analyst upgrades
Alkermes is gaining momentum after a Q1 beat and positive phase 3 LUMRYZ results, boosting confidence in its growing sleep-disorder franchise and broader neuroscience platform.
The news is likely bullish for ALKS, as stronger financials and a key clinical win support higher growth expectations and sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings